[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
January 2016

Computer-aided Therapeutics in Treating Autoimmune Encephalitis—Reply

Author Affiliations
  • 1University Lyon 1, University Lyon, Lyon, France
  • 2Hospices Civils de Lyon, Neuro-oncologie, Hôpital Neurologique, Bron, France
  • 3Institut de Biologie de l’Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, CNRS UMR 8197, INSERM U1024, Paris, France
  • 4Centre National de Référence pour les Syndromes Neurologiques Paranéoplasiques, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France
  • 5Lyon Neuroscience Research Center, Neuro-Oncology and Neuro-Inflammation Team, INSERM, UMR-S1028, CNRS, UMR-5292, Lyon, France
JAMA Neurol. 2016;73(1):128. doi:10.1001/jamaneurol.2015.3519

In Reply We read with interest Dr Avasarala’s letter in which he raised the need for more specific and efficient treatment in antibody-mediated encephalitides. Indeed, the development of adequate therapeutic approaches is hampered both by the lack of disease-specific drugs and because the rarity of those disorders prevents controlled treatment studies. Dr Avasarala proposes that the growing knowledge about the 3-dimensional structure of the involved antigens (eg, the N-methyl-D-aspartate receptor [NMDAR] or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor [AMPAR]) should be used to design peptides that could serve as decoys for pathogenic antibodies.